1 domain / 2 areas / 2 specializations
Numinus / Cedar Clinical Research
Data updated
Canadian psychedelic research-site and training infrastructure associated with Numinus and Cedar Clinical Research, with public evidence from MAPS-sponsored MDMA work and broader sponsor support.
Clinical Trial Infrastructure Snapshot
Site Networks & SMOsService Model
Hybrid
Service Coverage
2 countries
Psychedelic Experience
Verified Psychedelic Trial Experience
Last Source Check
Jun 18, 2026
Public Sources
2
Lifecycle Coverage
Service Coverage Countries
Phase Coverage
Capabilities
Research Update
Public-source profile available
Last checked Jun 18, 2026 across 2 sources.
Search Finding
Participant-facing psychedelic trial sites and therapist-training infrastructure with public MAPS and MindMed-related evidence.
Service Notes
Model as one integrated stakeholder for now. If Blossom later splits subsidiaries/business units, Cedar Clinical Research and Numinus Training can become separate records.
Linked Stakeholders
No linked stakeholders yet.
Linked Trials
A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)
Recruiting
A Phase 3 Trial of MM120 for Major Depressive Disorder (Emerge)
Active not recruiting
Phase III Long-term Extension Trial to Assess Safety and Efficacy of CYB003 in MDD (EXTEND) (EXTEND)
Enrolling by invitation
A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama)
Active not recruiting
A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Voyage)
Active not recruiting
A Study of a Psilocybin Analog (CYB003) in Humans With Major Depressive Disorder (APPROACH)
Recruiting
A Study of a N, N-dimethyltryptamine (DMT) Analog (CYB004) in Participants With Generalized Anxiety Disorder (GAD) With Depressive Symptoms
Active not recruiting
Psilocybin for Major Depressive Disorder (MDD) (uAspire)
Active not recruiting
BPL-003 Efficacy and Safety in Treatment Resistant Depression
Completed
Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD (COMP 006)
Active not recruiting
Efficacy, Safety, and Tolerability of COMP360 in Participants With TRD (COMP005)
Completed
A Dose-Finding Study of MM-120 for the Treatment of Anxiety Symptoms
Completed
A Multi-Site Open-Label Extension Study of MDMA-Assisted Psychotherapy for PTSD
Completed
A Study of Psilocybin for Major Depressive Disorder (MDD)
Completed
Source Evidence
MAPS trial dosing at Numinus
https://www.prnewswire.com/news-releases/numinus-completes-first-mdma-administration-in-ptsd-trial-sponsored-by-maps-301513700.html
Numinus 2026 infrastructure statement
https://www.nasdaq.com/press-release/numinus-wellness-responds-trump-executive-order-psychedelic-therapies-2026-04-20
Quick Facts
- HQ
- Vancouver Research clinic (city-level coordinate), Canada
- Website
- Visit